NCT04256707 · MORE INFO

Limitations, agreements, and source contact

Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment · Source last updated 2026-10-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

limitations And Caveats

description: The Combination therapy portion of the study was terminated prior to full enrollment for futility. Enrollment was halted as preliminary antitumor activity of selinexor was assessed by the Sponsor to be insufficiently competitive compared to currently available or anticipated future treatments.

point Of Contact

email: clinicaltrials@karyopharm.com
organization: Karyopharm Therapeutics Inc
phone: (888) 209-9326
title: Karyopharm Medical Information

Complete source fields

certain Agreement

pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

limitations And Caveats

description: The Combination therapy portion of the study was terminated prior to full enrollment for futility. Enrollment was halted as preliminary antitumor activity of selinexor was assessed by the Sponsor to be insufficiently competitive compared to currently available or anticipated future treatments.

point Of Contact

email: clinicaltrials@karyopharm.com
organization: Karyopharm Therapeutics Inc
phone: (888) 209-9326
title: Karyopharm Medical Information

Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0

Preserved source evidence · Not medical advice